P Halfon
Overview
Explore the profile of P Halfon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1084
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fratzl M, Bigotte P, Gorbenkov R, Goubet G, Halfon P, Kauffmann P, et al.
SLAS Technol
. 2024 Feb;
29(3):100119.
PMID: 38302059
Sexually transmitted infections (STI) remain one of the world's public health priorities: Nearly 400 million people are infected not only in emerging, but also in western countries. HIV, HBV and...
2.
Delshadi S, Fratzl M, Ramel O, Bigotte P, Kauffmann P, Kirk D, et al.
Lab Chip
. 2023 Feb;
23(4):645-658.
PMID: 36723037
Immunoassays are used for many applications in various markets, from clinical diagnostics to the food industry, generally relying on gold-standard ELISAs that are sensitive, robust, and cheap but also time-consuming...
3.
Cacoub P, Halfon P
Rev Med Interne
. 2022 Nov;
43(11):637-639.
PMID: 36333007
No abstract available.
4.
Stavris C, Chiche L, Charpin C, Dukan P, Doncarli C, Drouet H, et al.
Rev Med Interne
. 2022 Jul;
43(10):626-629.
PMID: 35908996
No abstract available.
5.
6.
Kostine M, Chiche L, Lazaro E, Halfon P, Charpin C, Arniaud D, et al.
Rev Med Interne
. 2017 Feb;
38(8):513-525.
PMID: 28214182
With "checkpoint inhibitors" targeting PD1/PD-1-ligands or CTLA-4/CD28 pathways, immunotherapy has profoundly modified therapeutic strategies in oncology. First approved in refractory metastatic neoplasms (melanoma and lung adenocarcinoma), it is now being...
7.
Rueger S, Bochud P, Dufour J, Mullhaupt B, Semela D, Heim M, et al.
Gut
. 2014 Sep;
64(10):1605-15.
PMID: 25214320
Objective: The natural course of chronic hepatitis C varies widely. To improve the profiling of patients at risk of developing advanced liver disease, we assessed the relative contribution of factors...
8.
9.
Maasoumy B, Cobb B, Bremer B, Luk K, Halfon P, Aslam S, et al.
Aliment Pharmacol Ther
. 2013 Nov;
39(1):85-92.
PMID: 24206524
Background: Early on-treatment virological response is one of the most important predictors for sustained virological response (SVR) to treatment of chronic hepatitis C virus (HCV) genotype 1 infection with triple...
10.
Sancho-Garnier H, Tamalet C, Halfon P, Leandri F, Le Retraite L, Djoufelkit K, et al.
Int J Cancer
. 2013 May;
133(11):2681-7.
PMID: 23712523
Today in France, low attendance to cervical screening by Papanicolaou cytology (Pap-smear) is a major contributor to the 3,000 new cervical cancer cases and 1,000 deaths that occur from this...